Cantor Fitzgerald Maintains Overweight on Cytokinetics, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Cytokinetics (NASDAQ:CYTK) and raises the price target from $59 to $65.
October 09, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Cytokinetics and raised the price target from $59 to $65.
The raised price target by Cantor Fitzgerald indicates a positive outlook for Cytokinetics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100